BeOne Medicines AG (NASDAQ:ONC) is one of the best healthcare stocks to buy for 2026. On January 13, at the 44th Annual J.P. Morgan Healthcare Conference, BeOne Medicines AG (NASDAQ:ONC) reiterated significant progress in its pipeline development.
BRUKINSA, a tyrosine kinase inhibitor, has achieved 74% six-year progression-free survival, compared with 32% with bendamustine plus rituximab, in treatment-naïve chronic lymphocytic leukemia. Sonrotoclax, its BCL2 inhibitor, has received regulatory approval, with an overall response rate of 86% in heavily pretreated CLL patients. The company is also advancing 15 new molecular entities into clinical trials and plans to deliver 8 to 10 additional candidates.
Earlier on January 7, Citizens reiterated a Market Perform rating and a $396 price target on the stock, impressed by robust efficacy data from the company’s phase 3 trial in gastric cancer patients. The expected approval of sonrotoclax, a next-generation BCL2 inhibitor, is also expected to trigger additional approval globally. Likewise, the research firm expects the company’s Brukinsa drug to generate $3.8 billion in 2025.
BeOne Medicines AG is a biotechnology company focused on discovering, developing, and commercializing innovative, affordable oncology treatments. It is known for products such as Brukinsa and Tevimbra and utilizes a worldwide network for R&D and manufacturing.
READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.
This article is originally published at Insider Monkey.
